Search Results

TREMFYA, the first and only selective interleukin (IL)-23 inhibitor therapy approved in the U.S. to treat both adults with active PsA and adults with moderate to severe plaque psoriasis (PsO), demonstrated low rates of structural damage progression and durable improvements in physical function at week 100 Approximately 80-90 percent of TREMFYA-treated patients who achieved improvements in joint signs and symptoms and low levels of disease activity at week 52 (ACR20/50 and MDA) maintained this response at week 100

For International Day of Persons with Disabilities, we’re celebrating how the company has committed to being a safe space for people with diverse physical, neurological and mental health abilities—and sees them as crucial business assets.

Health-related impact investments remain limited, even as the field now totals a $715 billion global market. J&J Impact Ventures is investing in purpose-driven entrepreneurs and their startups in the belief that as their businesses grow, so will their impact.

STELARA when used as a first-line therapy was associated with longer time in clinical remission or clinical response, including the postponing of surgery, among adult patients with moderately to severely active ulcerative colitis compared with usage as a second- or third-line therapy in a modelled analysis Bio-naïve patients with moderately to severely active Crohn’s disease started on STELARA showed higher rates of persistence at one year compared to adalimumab in a retrospective real-world evidence study

DePuy Synthes and the Johnson & Johnson Institute are rolling out a first-of-its-kind in Australia mobile training experience for surgeons and hospital staff to provide on-site, hands-on training for the VELYSTM Robotic-Assisted Solution. The mobile training lab brings innovative training solutions – incorporating virtual reality and novel surgical simulation technologies – to surgeons and their surgical teams at their clinical practice. The VELYS™ Robotic-Assisted Solution, indicated for use with the ATTUNE® Knee System for total knee arthroplasty, has recently been included on the Australian Register of Therapeutic Goods (ARTG).